Bertrand B.
- Country
- France
- Department
- Service de neurologie
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Phase III Randomized Double‑Blind Study of Fenebrutinib versus Teriflunomide for Efficacy and Safety in Adults with Relapsing Multiple Sclerosis
- TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis.
Data & Insights
Has run more than one trial at 108 of 316 partner sites.
Specializations
Multiple Sclerosis Management
The investigator specializes in treating relapsing-remitting multiple sclerosis (RRMS), with particular focus on innovative therapeutic approaches using anti-CD20 therapies including rituximab and ocrelizumab.
- Disease-modifying therapy optimization
- Treatment strategies for aging MS populations
- Comparative treatment efficacy studies
Expertise extends to evaluating therapeutic interventions in both active and stable MS patients.
Neurological Disorders
Active involvement in research concerning myelin oligodendrocyte glycoprotein antibody associated disease (MOG-AD) and related neurological conditions.
- Autoimmune neurological disorders
- Preventive treatment approaches
- Relapse prevention strategies
Focuses on developing treatment protocols for rare neuroimmunological conditions.
Treatment Innovation
Explores therapeutic de-escalation strategies and investigates enhanced dosing protocols for established treatments in neurological conditions.
- Dose optimization studies
- Long-term treatment outcomes
- Platform therapy transitions
Evaluates novel approaches to improve treatment efficacy and patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.